1. Home
  2. ALAR vs SNTI Comparison

ALAR vs SNTI Comparison

Compare ALAR & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alarum Technologies Ltd.

ALAR

Alarum Technologies Ltd.

N/A

Current Price

$1.39

Market Cap

13.3M

Sector

Technology

ML Signal

N/A

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

N/A

Current Price

$0.35

Market Cap

12.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALAR
SNTI
Founded
2013
2016
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.3M
12.1M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
ALAR
SNTI
Price
$1.39
$0.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$14.00
$8.50
AVG Volume (30 Days)
85.1K
190.6K
Earning Date
05-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.31
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$24.51
N/A
Revenue Next Year
$33.43
N/A
P/E Ratio
$44.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.51
$0.33
52 Week High
$17.25
$2.88

Technical Indicators

Market Signals
Indicator
ALAR
SNTI
Relative Strength Index (RSI) 21.66 35.47
Support Level N/A $0.33
Resistance Level $2.10 $0.40
Average True Range (ATR) 0.06 0.04
MACD 0.09 0.01
Stochastic Oscillator 4.57 14.48

Price Performance

Historical Comparison
ALAR
SNTI

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: